Drug Trial Radar · NCT05358249
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
74
Actual
Start
Oct 24, 2022
Primary completion
Sep 28, 2026
Study completion Sep 28, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.
Conditions
- KRAS G12C Mutant Solid Tumors
- Carcinoma, Non-Small Cell Lung
- Carcinoma, Non-Small-Cell Lung
- Non-Small Cell Lung Cancer
- Non-Small Cell Lung Carcinoma
- Nonsmall Cell Lung Cancer
- Colorectal Cancer
- Colorectal Carcinoma
- Colorectal Neoplasms
- Colorectal Tumors
- Neoplasms, Colorectal
Interventions
JDQ443Drug
KRAS G12C inhibitor, oral
trametinibDrug
MEK inhibitor, oral
RibociclibDrug
CDK4/6 inhibitor, oral
cetuximabBiological
EGFR inhibitor, intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose escalation: Incidence and severity of dose limiting toxicities (DLTs) of each combination treatment.Time frame: 28 days
- Dose escalation: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) by treatmentTime frame: 24 months
- Dose escalation: Frequency of dose interruptions and reductions, by treatmentTime frame: 24 months
- Dose Escalation: Dose intensity by treatmentTime frame: 24 months
- PhaseII: Overall Response Rate by Blinded Independent Review Committee (BIRC) per RECIST 1.1Time frame: 24 months
Locations
13 sites in 8 countries. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
NYU School of Medicine
New York, New York
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Seoul, Seoul, South Korea
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.